Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Sumitomo Dainippon Pharma Co., Ltd.
  6. Summary
    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO., LTD.

(4506)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
2243 2258 2169 2246 2278 Last
691400 2254300 1315700 796700 1038800 Volume
-1.10% +0.67% -3.94% +3.55% +1.42% Change
Estimated financial data (e)
Sales 2021 520 B 4 690 M 4 690 M
Net income 2021 30 811 M 278 M 278 M
Net Debt 2021 190 B 1 714 M 1 714 M
P/E ratio 2021 30,0x
Yield 2021 1,23%
Sales 2022 564 B 5 089 M 5 089 M
Net income 2022 49 263 M 445 M 445 M
Net Debt 2022 43 058 M 389 M 389 M
P/E ratio 2022 17,8x
Yield 2022 1,23%
Capitalization 905 B 8 165 M 8 170 M
EV / Sales 2021 2,11x
EV / Sales 2022 1,68x
Nbr of Employees 6 457
Free-Float 40,6%
More Financials
Company
Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other Overseas division is involved in the development of its products in... 
Sector
Pharmaceuticals
Calendar
06/24
More about the company
Ratings of Sumitomo Dainippon Pharma Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SUMITOMO DAINIPPON PHARMA CO., LTD.
06/03SUMITOMO DAINIPPON PHARMA  : Comments Regarding Media Article on Our Company
PU
05/28Nikkei 225 Surges 2.1% As Yen Slips Against US Dollar
MT
05/27Japanese shares jump nearly 2% as vaccine rollouts lift recovery hopes
RE
05/13SUMITOMO DAINIPPON PHARMA  : First AI designed Alzheimer's drug to enter clinica..
AQ
05/12SUMITOMO DAINIPPON PHARMA  : Supplementary Financial Data (IFRS) for the Year En..
PU
05/12SUMITOMO DAINIPPON PHARMA  : Investors Meeting Presentation for FY2020 (Year end..
PU
05/12SUMITOMO DAINIPPON PHARMA  : Notice of Change of Trade Name and Partial Amendmen..
PU
05/12SUMITOMO DAINIPPON PHARMA  : Announces Reviesd Mid-term Business Plan 2022 (FY20..
PU
05/12SUMITOMO DAINIPPON PHARMA CO., LTD.  : Annual results
CO
05/07SUMITOMO DAINIPPON PHARMA  : Announces Acquisition of Rights for Certain Sinovan..
PU
05/06SUMITOMO DAINIPPON PHARMA  : Announces Investment in Special Purpose Acquisition..
PU
05/06SUMITOMO DAINIPPON PHARMA  : Consolidated Subsidiary Enzyvant Transfers its RVT-..
AQ
05/06Sumitomo Dainippon Pharma to Invest in Roivant Sciences
MT
04/26SUMITOMO DAINIPPON PHARMA  : Sumitomo Dainippon Pharma Announces Revisions to It..
AQ
04/26Sumitomo Dainippon Pharma Raises Earnings Forecast for Fiscal Year
MT
More news
News in other languages on SUMITOMO DAINIPPON PHARMA CO., LTD.
06/23POXEL  : le titre en hausse après un feu vert au Japon
05/03La biotech Roivant entre en bourse via le SPAC Montes Archimedes
04/20Les biotechs suisses ont continué à attirer les capitaux en 2020
2020TOKYO STOCK EXCHANGE : Borsa Tokyo, Nikkei oltre massimi 30 anni su speranze inc..
2020MÄRKTE ASIEN/Nikkei macht 2,7%-Satz auf 30-Jahres-Hoch
More news
Chart SUMITOMO DAINIPPON PHARMA CO., LTD.
Duration : Period :
Sumitomo Dainippon Pharma Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 9
Last Close Price 2 278,00 JPY
Average target price 1 816,67 JPY
Spread / Average Target -20,3%
EPS Revisions
Managers and Directors
NameTitle
Hiroshi Nomura President & Representative Director
Masayo Tada Chairman
Yoshiharu Ikeda GM-Production, Head-Research & Technology
Yutaka Atomi Independent Outside Director
Saeko Arai Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
SUMITOMO DAINIPPON PHARMA CO., LTD.49.57%8 165
JOHNSON & JOHNSON3.34%428 269
ROCHE HOLDING AG10.19%321 632
PFIZER, INC.6.09%218 590
NOVARTIS AG1.55%207 926
ABBVIE INC.6.39%201 349